Its ability to activate the Nrf2 antioxidant pathway and reduce NF-κB-driven inflammation makes SB216763 a promising candidate for therapeutic intervention in CKD, supporting both podocyte and tubular cell survival. Here, NFKB1 is linked to chronic kidney disease.